MedTrace Logo

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

NCT04787354 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 976

Last updated 2022-02-21

No results posted yet for this study

Summary

This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8 cycles of XELOX).

Conditions

Interventions

DRUG

Oxaliplatin

Oxaliplatin: 130 mg/m2/day

DRUG

Capecitabine

Capecitabine: 2,000 mg/m2/day

Sponsors & Collaborators

  • Hallym University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2024-12-31
Completion
2027-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04787354 on ClinicalTrials.gov